Vopratelimab (MouseIgG2a) is a monoclonal antibody that selectively targets the inducible T-cell co-stimulator (ICOS). The variable region of Vopratelimab (MouseIgG2a) matches that of Vopratelimab, while its constant region is based on the mouse IgG2a sequence. Vopratelimab (MouseIgG2a) promotes anti-tumor immune responses and enhances the efficacy of combination therapy with anti-PD-1.

Aducanumab (Mouse IGG2a) administered at 0.25-0.3 mg/kg via intraperitoneal injection in a regimen of four doses on days 7, 10, 14, and 17, demonstrates significant antitumor efficacy (70% tumor regression) and sustained systemic immunity in the Sa1/N fibrosarcoma mouse model. Similarly, at 0.25 mg/kg in two doses on days 6 and 11, it shows notable antitumor activity with long-term protection in the B16-SIY tumor mouse model.